Efficacy of atosiban for repeated embryo implantation failure: A systematic review and meta-analysis

Ruxin Wang, Haixia Huang, Yong Mong Tan, Xia Gui-chengFrontiers in Endocrinology 2023 · DOI

This systematic review and meta-analysis, published in Frontiers in Endocrinology, evaluates whether the drug atosiban can improve pregnancy outcomes for women facing one of the most difficult challenges in fertility treatment: repeated embryo implantation failure (RIF). By synthesizing data from seven clinical studies, the researchers found that atosiban significantly increases clinical pregnancy and live birth rates, likely by reducing uterine contractions during the embryo transfer process.

TL;DR

Atosiban, an oxytocin antagonist, significantly improves clinical pregnancy and live birth rates for women with repeated embryo implantation failure (RIF) undergoing IVF. By "quieting" the uterus during embryo transfer, the drug increases the likelihood of successful implantation without increasing the risk of miscarriage or ectopic pregnancy.

What Problem Does This Paper Address?

In the world of in vitro fertilization (IVF), repeated embryo implantation failure (RIF) is a frustrating "black box." Even when high-quality embryos are transferred, they sometimes fail to stick. While much research focuses on embryo genetics, this paper looks at the "soil"—the uterine environment.

During embryo transfer, the physical manipulation of the cervix and high hormonal levels can trigger uterine contractions (peristalsis). These contractions can physically displace the embryo or interfere with the delicate molecular signaling required for it to burrow into the uterine lining. Atosiban, a drug originally developed to stop preterm labor, blocks oxytocin and vasopressin receptors to relax the uterine muscle. However, clinical evidence for its use in IVF has been inconsistent, leading the authors to perform this comprehensive meta-analysis.

Methods

The authors conducted a systematic review following the PRISMA guidelines, searching five major databases (including PubMed and EMBASE) through December 2022. They used the PICOS framework to standardize their search:

  • Population: Patients with RIF undergoing IVF-ET.
  • Intervention: Atosiban administration around the time of embryo transfer.
  • Comparison: Placebo or no treatment.
  • Outcomes: Pregnancy rates (clinical, live birth, etc.).
  • Study Design: Randomized controlled trials (RCTs) and cohort studies.

They utilized StataMP 17.0 to calculate Risk Ratios (RR) and employed subgroup analyses to see if the results held up across different study types and diagnostic criteria for RIF.

Datasets

The meta-analysis synthesized data from 7 studies involving a total of 1,958 participants (903 in the atosiban group and 1,055 in the control group). The included studies consisted of:

  • 2 Prospective Randomized Controlled Trials (RCTs)
  • 1 Prospective cohort study
  • 4 Retrospective cohort studies

The studies were primarily conducted in single-center settings in China, involving both fresh and frozen-thawed embryo transfer cycles.

Key Insights and Ideas

  • The "Quiet Uterus" Hypothesis: The results strongly support the theory that uterine hyper-motility is a major barrier to implantation in RIF patients. Reducing these "waves" of contraction creates a more stable window for the embryo.
  • Consistent Benefits Across Definitions: RIF is notoriously difficult to define (some say 2 failed cycles, others say 3). Interestingly, atosiban showed significant benefits regardless of whether the patient had 2 or 3+ previous failures.
  • Safety Profile: One of the most important "aha" moments was the lack of adverse effects. Atosiban improved the "good" outcomes (pregnancy) without increasing "bad" outcomes like miscarriages, multiple pregnancies, or ectopic pregnancies.
  • Dosing Nuance: The review noted that while most studies used a bolus dose (6.75mg) before transfer, some evidence suggests that a single bolus might be just as effective as—or even superior to—a bolus followed by a long-term infusion.

Key Results

The quantitative findings were robust across several metrics:

  • Clinical Pregnancy Rate (CPR): Atosiban was associated with a 54% increase in the likelihood of clinical pregnancy (RR=1.54, 95% CI: 1.365–1.735).
  • Live Birth Rate (LBR): The likelihood of a successful live birth increased by 58% (RR=1.58, 95% CI: 1.18–2.11).
  • Implantation Rate (IR): The rate of successful attachment per embryo also improved significantly (RR=1.54).
  • Positive Pregnancy Test Rate (PPTR): Showed a 32% improvement (RR=1.32).
  • No Significant Difference was found in miscarriage rates (RR=0.94) or ectopic pregnancy rates (RR=0.64), suggesting the drug is safe for the developing pregnancy.

Limitations and Future Work

The authors highlight several areas for caution:

  • Study Quality: Only two of the seven studies were RCTs, and some lacked double-blinding, which can introduce bias.
  • Heterogeneity in Protocols: There was significant variation in how RIF was diagnosed and how atosiban was administered (timing and dosage).
  • Age Constraints: Most participants were aged 20–45. The efficacy in older patients (who may have different uterine dynamics) requires more targeted study.
  • Future Direction: The authors call for large-scale, multi-center, double-blind RCTs to standardize the protocol and confirm if atosiban should become a standard "add-on" for RIF patients.

Summary updated

Abstract

For women who are undergoing IVF-ET and have experienced repeated embryo implantation failure, atosiban may be an important factor in enhancing pregnancy outcomes. To confirm this conclusion, more thorough, prospective randomized controlled studies of sizable sample sizes with well design are required.
BibTeX
@inproceedings{wang2023efficacy,
  author = {Ruxin Wang and Haixia Huang and Yong Mong Tan and Xia Gui-cheng},
  title = {{Efficacy of atosiban for repeated embryo implantation failure: A systematic review and meta-analysis}},
  booktitle = {Frontiers in Endocrinology},
  year = {2023},
  doi = {10.3389/fendo.2023.1161707},
}
Figure